Connective tissue and its growth factor CTGF distinguish the morphometric and molecular remodeling of the bladder in a model of neurogenic bladder

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 9, 2012, Pages

  Altuntas, Cengiz Z ^a   Daneshgari, Firouz ^a   Izgi, Kenan ^a,b   Bicer, Fuat ^a,b   Ozer, Ahmet ^a,c   Sakalar, Cagri ^d   Grimberg, Kerry O ^a   Sayin, Ismail ^a,c   Tuohy, Vincent K ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bladder remodeling; Connective tissue growth factor; Multiple sclerosis; Transforming growth factor 3

Indexed keywords

EID: 84868352665     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00273.2012     Document Type: Article

References (31)

1. Al-Izki S, Pryce G, Giovannoni G, Baker D. Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography. Mult Scler 15: 795-801, 2009.
2. Altuntas CZ, Daneshgari F, Liu G, Fabiyi A, Kavran M, Johnson JM, Gulen MF, Jaini R, Li X, Frenkl TL, Tuohy VK. Bladder dysfunction in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 203: 58-63, 2008.
3. Borello-France D, Leng W, O'Leary M, Xavier M, Erickson J, Chancellor MB, Cannon TW. Bladder and sexual function among women with multiple sclerosis. Mult Scler 10: 455-461, 2004.
4. Brigstock DR. Inhibitors of connective tissue growth factor (CCN2)-mediated fibrogenesis: underlying mechanisms and prospects for antifibrotic therapy. In: CCN Proteins in Health and Disease. New York, NY: Springer Science-Business Media, 2010.
5. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J Am Soc Nephrol 17: 2484-2494, 2006.
6. Cannito S, Novo E, di Bonzo LV, Busletta C, Colombatto S, Parola M. Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxidants Redox Signal 12: 1383-1430, 2010.
7. Chaqour B, Whitbeck C, Han JS, Macarak E, Horan P, Chichester P, Levin R. Cyr61 and CTGF are molecular markers of bladder wall remodeling after outlet obstruction. Am J Physiol Endocrinol Metab 283: E765-E774, 2002.
8. Chung CW, Zhang QL, Qiao LY. Endogenous nerve growth factor regulates collagen expression and bladder hypertrophy through akt and MAPK pathways during cystitis. J Biol Chem 285: 4206-4212, 2010.
9. Dupont MC, Spitsbergen JM, Kim KB, Tuttle JB, Steers WD. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 166: 1111-1118, 2001.
10. Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58: 1389-1399, 2000.
11. Hanai T, Ma FH, Matsumoto S, Park YC, Kurita T. Partial outlet obstruction of the rat bladder induces a stimulatory response on proliferation of the bladder smooth muscle cells. Int Urol Nephrol 34: 37-42, 2002.
12. Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, Liu L, Qian W, Ransohoff RM, Bergmann C, Stohlman S, Tuohy VK, Li X. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 32: 414-425, 2010.
13. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 21: 467-476, 2004.
14. Lincoln J, Haven AJ, Sawyer M, Burnstock G. The smooth muscle of rat bladder in the early stages of streptozotocin-induced diabetes. Br J Urol 56: 24-30, 1984.
15. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol 161: 743-757, 1999.
16. Liu FY, Xiao L, Peng YM, Duan SB, Liu H, Liu YH, Ling GH, Yuan F, Chen JX, Fu X, Zhu JL. Inhibition effect of small interfering RNA of connective tissue growth factor on the expression of vascular endothelial growth factor and connective tissue growth factor in cultured human peritoneal mesothelial cells. Chin Med J (Engl) 120: 231-236, 2007.
17. Liu G, Daneshgari F. Temporal diabetes-and diuresis-induced remodeling of the urinary bladder in the rat. Am J Physiol Regul Integr Comp Physiol 291: R837-R843, 2006.
18. Nagatomi J, Gloeckner DC, Chancellor MB, DeGroat WC, Sacks MS. Changes in the biaxial viscoelastic response of the urinary bladder following spinal cord injury. Ann Biomed Eng 32: 1409-1419, 2004.
19. Okragly AJ, Niles AL, Saban R, Schmidt D, Hoffman RL, Warner TF, Moon TD, Uehling DT, Haak-Frendscho M. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol 161: 438-441, 1999.
20. Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 19: 133-144, 2008.
21. Sobel RA, Tuohy VK, Lu ZJ, Laursen RA, Lees MB. Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein. J Neuropathol Exp Neurol 49: 468-479, 1990.
22. Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 26: 565-571, 2005.
23. Tran CM, Markova D, Smith HE, Susarla B, Ponnappan RK, Anderson DG, Symes A, Shapiro IM, Risbud MV. Regulation of CCN2/connective tissue growth factor expression in the nucleus pulposus of the intervertebral disc: Role of smad and activator protein 1 signaling. Arthritis Rheum 62: 1983-1992, 2010.
24. Tuohy VK, Lu Z, Sobel RA, Laursen RA, Lees MB. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol 142: 1523-1527, 1989.
25. Uvelius B. Detrusor smooth muscle in rats with alloxan-induced diabetes. J Urol 136: 949-952, 1986.
26. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189, 2006.
27. Vizzard MA. Changes in urinary bladder neurotrophic factor mrna and ngf protein following urinary bladder dysfunction. Exp Neurol 161: 273-284, 2000.
28. Wein AJ. Lower urinary tract dysfunction in neurologic injury and disease. In: Campbell-Walsh Urology, edited by Wein AJ. Philadelphia, PA: Elsevier, 2007.
29. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.
30. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 183: 1777-1788, 1996.
31. Zhang X, Seftel A, Disanto ME. Blebbistain, a myosin II inhibitor, as a novel strategy to regulate detrusor contractility in a rat model of partial bladder outlet obstruction. Plos One 6: e25958, 2011.